Show Search Form
human indexable | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
published | |||||||||||
registered interest | |||||||||||
answer date | |||||||||||
date | |||||||||||
date tabled | |||||||||||
ddp created | |||||||||||
answering body |
|
||||||||||
question status | Tabled | ||||||||||
answering dept id | 17 | ||||||||||
answering dept short name | Health | ||||||||||
answering dept sort name | Health | ||||||||||
ddp modified |
|
||||||||||
hansard heading | Cerliponase Alfa | ||||||||||
house id | 1 | ||||||||||
identifier | 4139 | ||||||||||
legislature |
|
||||||||||
parliament number | 57 | ||||||||||
question first answered |
|
||||||||||
question text | To ask the Secretary of State for Health, what the estimated average annual cost is to the NHS of providing Brineura (Cerliponase Alfa) to someone with the CLN2 variant of Batten Disease. | ||||||||||
session |
|
||||||||||
session number | 1 | ||||||||||
tabling member constituency | Nottingham North | ||||||||||
tabling member printed |
|
||||||||||
title | House of Commons Tabled Parliamentary Question 2017/19 4139 | ||||||||||
type |
|
||||||||||
uin | 4139 | ||||||||||
version | 1 | ||||||||||
written parliamentary question type | Ordinary | ||||||||||
answer | answer | ||||||||||
creator |
|
||||||||||
publisher |
|
||||||||||
tabling member |
|